.

0 (hodnocen0 x )

EB

ONLINE

Cham : Springer International Publishing AG, 2022

1 online resource (221 pages)

ISBN 9783030943530 (electronic bk.)

ISBN 9783030943523

Print version: Kroger, Nicolaus The EBMT/EHA CAR-T Cell Handbook Cham : Springer International Publishing AG,c2022 ISBN 9783030943523

Resistance to Lymphodepletion and Immunosuppression -- Removal of HLA for Evading Host Immunity -- Manufacturing Aspects of ’Off-the-Shelf’ CARs -- References.

6: Providing the Starting Material to the Manufacturer of an Approved and Commercially Available Autologous CAR-T Cell Treatment -- Introduction -- References -- 7: Receiving, Handling, Storage, Thawing, Distribution, and Administration of CAR-T Cells Shipped from the Manufacturing Facility -- Definition -- Administration -- Patients Treated with CAR-T Cells: New Missions for the Hospital Pharmacist -- References -- 8: Point-of-Care Production of CAR-T Cells -- GMP Vector Production -- Manufacturing CAR-T Cells -- References -- 9: Off-the-Shelf Allogeneic CAR-T Cells or Other Immune Effector Cells -- Strategies to Avoid Graft Versus Host Disease (GvHD) -- Genome Edited abTCR-Deleted T Cells -- Virus-Specific T (VST) Cells -- Alternative Immune Effector Cells -- Strategies to Avoid Host-Mediated Rejection of Allogeneic Immune Cells ---

Resistance to Lymphodepletion and Immunosuppression -- Removal of HLA for Evading Host Immunity -- Manufacturing Aspects of ’Off-the-Shelf’ CARs -- References.

Intro -- Preface -- Contents -- Part I: The Science Behind CAR-T Cells -- 1: Structure of and Signalling Through Chimeric Antigen Receptor -- References -- 2: Genetic Engineering of Autologous or Allogeneic Immune Effector Cells -- References -- 3: What Defines a Good Tumour Antigen? -- Tumour-Specific Antigens (TSAs) -- Multiple Tumour Antigens Resulting in a ’Tumour-Specific Phenotype’ -- Lineage-Specific and Differentiation Antigens -- Lineage-Specific Polymorphic/Heterogeneic Antigens -- References -- 4: Tumour Escape from CAR-T Cells -- Immune Escape and CAR-T Cell Resistance Related to Antigen Loss -- Immune Dysfunction and Exhaustion of CAR-T Cells -- Microenvironment-Mediated Tumour Resistance to CAR-T Cells -- References -- 5: CART Initiatives in Europe -- References -- Part II: Manufacturing CAR-T Cells: The Supply Chain ---

Monitoring of Additional Immune Parameters (Non-CAR-T, B, and NK Cells and Cytokines) -- References -- 36: Long-Term Follow-Up and Late Effects -- Follow-Up and Programmes -- Post-authorisation Safety Surveillance (PASS) -- JACIE -- References -- Part V: Access to CAR-T Cells -- 37: The Regulatory Framework for CAR-T Cells in Europe: Current Status and Foreseeable Changes AND Centre Qualification by Competent Authorities and Manufacturers -- Current Framework -- Hospital Exemption -- Role of Academia -- Health Technology Assessment -- Future Focus -- Centre Qualification by Competent Authorities and Manufacturers -- Shared Goals -- Centre Assessment -- Centre Auditing -- Centre Training -- References -- 38: How Can Accreditation Bodies, Such as JACIE or FACT, Support Centres in Getting Qualified? -- References -- 39: Educational Needs for Physicians -- References -- 40: Education Needs for Nurses in Adult and Paediatric Units -- Apheresis and Cell Collection -- Cell Infusion -- Patient Monitoring -- Toxicity Management -- Discharge -- Long-Term Follow Up -- Paediatric Considerations -- References -- 41: Role of Pharmacists -- References -- 42: Educational Needs for Cell Processing Facility Personnel -- 43: GoCART -- 44: Patient Referral -- References -- 45: Treatment Coverage and Reimbursement -- 46: The Value of CAR-T-cell Immunotherapy in Cancer -- References -- 47: What do Patients Want? The Importance of Patient-reported Outcomes -- References.

To Bridge or Not to Bridge in Relapsed and Refractory (R/R) Aggressive B-Cell Lymphoma? -- Which Bridging Therapy? -- Response Rate to Bridging Therapy and Subsequent CAR-T Cell Therapy -- References -- 23: Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL -- References -- 24: Bridging Chemotherapy: Multiple Myeloma -- Should All MM Patients Receive Bridging Therapy? -- Timeframe to Use Bridging Treatments -- Choice of Treatment -- References -- 25: Lymphodepleting Conditioning Regimens -- References -- 26: Management of Cytokine Release Syndrome (CRS) and HLH -- Cytokine Release Syndrome (CRS) -- Definition and Occurrence -- Diagnosis -- Clinical Symptoms, Laboratory Diagnosis, Differential Diagnosis, and Predictive Factors -- Management -- Anti-Cytokines -- Steroids -- Antibiotics -- sHLH/MAS -- References -- 27: Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) -- Further Reading -- 28: Management of Hypogammaglobulinaemia and B-Cell Aplasia -- References -- 29: Management of Myelotoxicity (Aplasia) and Infectious Complications -- References -- 30: Management of Other Toxicities -- Considerations for Patients Undergoing CAR-T Cell Therapy -- References -- 31: ICU -- References -- 32: Post-CAR-T Cell Therapy (Consolidation and Relapse): Acute Lymphoblastic Leukaemia -- Management of Relapsed B-ALL After CD19 CAR-T Cell Therapy -- CD19-Positive Disease After CD19 CAR-T Cell Therapy -- CD19-Negative Disease After CD19 CAR-T Cell Therapy -- References -- 33: Post-CAR-T Cell Therapy (Consolidation and Relapse): Lymphoma -- References -- 34: Post-CAR-T Cell Therapy (Consolidation and Relapse): Multiple Myeloma -- References -- 35: Immune Monitoring -- Molecular Monitoring of CAR-T Cells via Digital PCR (dPCR) -- Flow Cytometry Monitoring of CAR-T Cells.

Monitoring of Additional Immune Parameters (Non-CAR-T, B, and NK Cells and Cytokines) -- References -- 36: Long-Term Follow-Up and Late Effects -- Follow-Up and Programmes -- Post-authorisation Safety Surveillance (PASS) -- JACIE -- References -- Part V: Access to CAR-T Cells -- 37: The Regulatory Framework for CAR-T Cells in Europe: Current Status and Foreseeable Changes AND Centre Qualification by Competent Authorities and Manufacturers -- Current Framework -- Hospital Exemption -- Role of Academia -- Health Technology Assessment -- Future Focus -- Centre Qualification by Competent Authorities and Manufacturers -- Shared Goals -- Centre Assessment -- Centre Auditing -- Centre Training -- References -- 38: How Can Accreditation Bodies, Such as JACIE or FACT, Support Centres in Getting Qualified? -- References -- 39: Educational Needs for Physicians -- References -- 40: Education Needs for Nurses in Adult and Paediatric Units -- Apheresis and Cell Collection -- Cell Infusion -- Patient Monitoring -- Toxicity Management -- Discharge -- Long-Term Follow Up -- Paediatric Considerations -- References -- 41: Role of Pharmacists -- References -- 42: Educational Needs for Cell Processing Facility Personnel -- 43: GoCART -- 44: Patient Referral -- References -- 45: Treatment Coverage and Reimbursement -- 46: The Value of CAR-T-cell Immunotherapy in Cancer -- References -- 47: What do Patients Want? The Importance of Patient-reported Outcomes -- References.

Part III: Clinical Indications for CAR-T Cells -- 10: Paediatric Acute Lymphoblastic Leukaemia (ALL) -- References -- 11: Adult Acute Lymphoblastic Leukaemia -- CAR-T Cell Therapy for Adult ALL -- Consolidation After CAR-T Cell Therapy -- Relapse After CAR-T Cell Therapy -- References -- 12: Diffuse Large B Cell Lymphoma and Primary Mediastinal Lymphoma -- Patient Population to Consider: Lymphoma-Specific Aspects -- Treatment History -- Remission Status and Tumour Bulk Prior to CAR-T Cell Infusion -- Histology -- Patient Population to Consider: Patient-Specific Aspects -- Alternative Treatments -- References -- 13: Mantle Cell Lymphoma -- Clinical Indications for CAR-T Cells -- Critical Evaluation -- References -- 14: Chronic Lymphocytic Leukaemia -- Clinical Development of CAR-T Cells for CLL -- Current Indications for CAR-T Cells in the Treatment Landscape of CLL -- Prospective Studies of Autologous Anti-CD19 CAR-T Cell Therapy for CLL -- References -- 15: Indolent Lymphomas -- References -- 16: Multiple Myeloma -- References -- 17: Developments in Other Haematological Malignancies: Other Lymphoid Malignancies -- Target Antigens -- CAR-T Development in T Cell Malignancies -- Bibliography -- 18: Myeloid Malignancies -- Single or Dual Antigen Targeting? -- Molecular Engineering of the Chimeric Receptor and Alternative Cell Sources -- References -- 19: Developments in Solid Tumours -- References -- Part IV: Clinical Management of Patients Treated with CAR-T Cells -- 20: Bridging Chemotherapy: Adult Acute Lymphoblastic Leukaemia -- References -- Further Reading -- 21: Bridging to CAR-T Cells in Children, Adolescents, and Young Adults with ALL -- The Importance of the Bridge -- Is There a Place for Immunotherapy? -- References -- 22: Bridging Chemotherapy: Relapsed/Refractory Aggressive B-Cell Lymphoma.

To Bridge or Not to Bridge in Relapsed and Refractory (R/R) Aggressive B-Cell Lymphoma? -- Which Bridging Therapy? -- Response Rate to Bridging Therapy and Subsequent CAR-T Cell Therapy -- References -- 23: Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL -- References -- 24: Bridging Chemotherapy: Multiple Myeloma -- Should All MM Patients Receive Bridging Therapy? -- Timeframe to Use Bridging Treatments -- Choice of Treatment -- References -- 25: Lymphodepleting Conditioning Regimens -- References -- 26: Management of Cytokine Release Syndrome (CRS) and HLH -- Cytokine Release Syndrome (CRS) -- Definition and Occurrence -- Diagnosis -- Clinical Symptoms, Laboratory Diagnosis, Differential Diagnosis, and Predictive Factors -- Management -- Anti-Cytokines -- Steroids -- Antibiotics -- sHLH/MAS -- References -- 27: Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) -- Further Reading -- 28: Management of Hypogammaglobulinaemia and B-Cell Aplasia -- References -- 29: Management of Myelotoxicity (Aplasia) and Infectious Complications -- References -- 30: Management of Other Toxicities -- Considerations for Patients Undergoing CAR-T Cell Therapy -- References -- 31: ICU -- References -- 32: Post-CAR-T Cell Therapy (Consolidation and Relapse): Acute Lymphoblastic Leukaemia -- Management of Relapsed B-ALL After CD19 CAR-T Cell Therapy -- CD19-Positive Disease After CD19 CAR-T Cell Therapy -- CD19-Negative Disease After CD19 CAR-T Cell Therapy -- References -- 33: Post-CAR-T Cell Therapy (Consolidation and Relapse): Lymphoma -- References -- 34: Post-CAR-T Cell Therapy (Consolidation and Relapse): Multiple Myeloma -- References -- 35: Immune Monitoring -- Molecular Monitoring of CAR-T Cells via Digital PCR (dPCR) -- Flow Cytometry Monitoring of CAR-T Cells.

001896598

express

(Au-PeEL)EBL6884928

(MiAaPQ)EBC6884928

(OCoLC)1299386533